At the 61st ASH Annual Meeting & Exposition, Louis Williams, NYU Langone Medical Center, provides a snapshot of his recent article with Oncology & Hematology (US) exploring genetic segmentation and targeted therapeutics for multiple myeloma.
1. How has increased understanding of the molecular biology of multiple myeloma impacted on risk stratification of patients? (0:05)
2. Could you tell us a little about B-cell maturation antigen targeted therapies? (1:02)
3. What other emerging targeted therapies seem promising? (2:34)
4. With so many new therapies available, how can we best incorporate them into the treatment paradigm? (3:56)
5. What other pathways are potential therapeutic targets? (5:28)
Louis Williams has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Shaji Kumar, ASH 2022: Highlights in older, frail transplant ineligible patients with multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Abstract 4553: Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (00:25-00:57) Abstract 569: A Dexamethasone Sparing-Regimen […]
Shaji Kumar, ASH 2022: Updated efficacy analysis from the phase III MAIA study in newly-diagnosed multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the updated efficacy analysis from the phase III MAIA study presented at the recent ASH 2022 congress. There were also some additional post-hoc efficacy analyses on key subgroups (Abstracts 4553 and 3245). Abstract 3245: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!